Abstract
In this article we present an update on the pharmacokinetic, pharmacodynamic and clinical studies of the parenteral glycoprotein IIb/IIIa receptor inhibitors available in the Netherlands. These are abciximab (Reopro®), eptifibatide (Integreline®) and tirofiban (Aggrastat®). Glycoprotein IIb/IIIa receptor inhibitors appear to be effective only in combination with percutaneous coronary interventions. The application of glycoprotein IIb/IIIa receptor inhibitors without percutaneous coronary interventions has limited value. Glycoprotein IIb/IIIa receptor inhibitors remain less effective than expected on theoretical grounds. Lots of studies have been performed with inconclusive results. Therefore little answers are available.
Translated title of the contribution | Many studies, few answers. Glycoprotein IIb/IIIa receptor inhibitors |
---|---|
Original language | Dutch |
Pages (from-to) | 746-750 |
Number of pages | 5 |
Journal | Pharmaceutisch Weekblad |
Volume | 138 |
Issue number | 21 |
Publication status | Published - 23 May 2003 |
Keywords
- Abciximab
- Angioplasty, transluminal, percutaneous coronary
- Eptifibatide
- Glycoprotein IIb/IIIa receptor inhibitors
- Myocardial ischemia
- Tirofiban